AIM: To study whether the glucocorticoid receptor (GR/NR3C1) gene haplotypes influence the steroid therapy outcome in inflammatory bowel disease (IBD). METHODS: We sequenced all coding exons and flanking intronic sequences of the NR3C1 gene in 181 IBD patients, determined the single nucleotide polymorphisms, and predicted the NR3C1 haplotypes. Furthermore, we investigated whether certain NR3C1 haplotypes are significantly associated with steroid therapy outcomes. RESULTS: We detected 13 NR3C1 variants, which led to the formation of 17 different haplotypes with a certainty of > 95% in 173 individuals. The three most commonly occurring haplotypes were included in the association analysis of the influence of haplotype on steroid therapy outcome or IBD activity. None of the NR3C1 haplotypes showed statistically significant association with glucocorticoid therapy success. CONCLUSION: NR3C1 haplotypes are not related to steroid therapy outcome.
AIM: To study whether the glucocorticoid receptor (GR/NR3C1) gene haplotypes influence the steroid therapy outcome in inflammatory bowel disease (IBD). METHODS: We sequenced all coding exons and flanking intronic sequences of the NR3C1 gene in 181 IBDpatients, determined the single nucleotide polymorphisms, and predicted the NR3C1 haplotypes. Furthermore, we investigated whether certain NR3C1 haplotypes are significantly associated with steroid therapy outcomes. RESULTS: We detected 13 NR3C1 variants, which led to the formation of 17 different haplotypes with a certainty of > 95% in 173 individuals. The three most commonly occurring haplotypes were included in the association analysis of the influence of haplotype on steroid therapy outcome or IBD activity. None of the NR3C1 haplotypes showed statistically significant association with glucocorticoid therapy success. CONCLUSION:NR3C1 haplotypes are not related to steroid therapy outcome.
Authors: Valérie Pittet; Pascal Juillerat; Christian Mottet; Christian Felley; Pierluigi Ballabeni; Bernard Burnand; Pierre Michetti; John-Paul Vader Journal: Int J Epidemiol Date: 2008-09-09 Impact factor: 7.196
Authors: R K Weersma; P C F Stokkers; A A van Bodegraven; R A van Hogezand; H W Verspaget; D J de Jong; C J van der Woude; B Oldenburg; R K Linskens; E A M Festen; G van der Steege; D W Hommes; J B A Crusius; C Wijmenga; I M Nolte; G Dijkstra Journal: Gut Date: 2008-09-29 Impact factor: 23.059
Authors: Marieke J H J Dekker; Erica L T van den Akker; Jan Willem Koper; Laura Manenschijn; Karin Geleijns; Liselotte Ruts; Wouter van Rijs; Anne P Tio-Gillen; Pieter A van Doorn; Steven W J Lamberts; Bart C Jacobs Journal: J Peripher Nerv Syst Date: 2009-06 Impact factor: 3.494
Authors: Elisabeth F C van Rossum; Jan W Koper; Nannette A T M Huizenga; André G Uitterlinden; Joop A M J L Janssen; Albert O Brinkmann; Diederick E Grobbee; Frank H de Jong; Cornelia M van Duyn; Huibert A P Pols; Steven W J Lamberts Journal: Diabetes Date: 2002-10 Impact factor: 9.461
Authors: Lisa M L van Winsen; Laura Manenschijn; Elisabeth F C van Rossum; J Bart A Crusius; Bart A Crusius; Jan Willem Koper; Chris H Polman; Bernard M J Uitdehaag Journal: J Clin Endocrinol Metab Date: 2009-03-24 Impact factor: 5.958
Authors: Kacper A Wojtal; Jyrki J Eloranta; Petr Hruz; Heike Gutmann; Jürgen Drewe; Alex Staumann; Christoph Beglinger; Michael Fried; Gerd A Kullak-Ublick; Stephan R Vavricka Journal: Drug Metab Dispos Date: 2009-06-01 Impact factor: 3.922
Authors: Shannon D Whirledge; Christine M Jewell; Lisa M Barber; Xiaojiang Xu; Kevin S Katen; Stavros Garantziotis; John A Cidlowski Journal: Lab Invest Date: 2017-07-31 Impact factor: 5.662
Authors: Sarah Tayler; Katarina Hazuchova; Anna Riddle; James W Swann; Barbara Glanemann Journal: J Vet Intern Med Date: 2022-06-10 Impact factor: 3.175
Authors: Michał Panek; Tadeusz Pietras; Artur Fabijan; Maciej Miłanowski; Lukasz Wieteska; Paweł Górski; Piotr Kuna; Janusz Szemraj Journal: Exp Ther Med Date: 2012-11-13 Impact factor: 2.447